广药集团强势切入创新药赛道

Core Viewpoint - Guangzhou Pharmaceutical Group is actively engaging in strategic transformation by exploring AI drug development, traditional pharmaceutical transitions, and innovative drug layouts, signaling a significant shift in the Chinese pharmaceutical industry [1][3]. Group 1: Company Actions - The company has initiated a series of proactive measures, including on-site visits, research exchanges, and partnership signings, to enhance its strategic positioning [1]. - Under the leadership of Chairman Li Xiaojun, the company has been frequently connecting with high-end resource platforms and has conducted extensive research on over 20 peer pharmaceutical companies [1][2]. Group 2: Industry Context - The company's transformation reflects a broader trend in the Chinese pharmaceutical industry, where traditional pharmaceutical giants are evolving to meet modern challenges and opportunities [3]. - The focus on AI drug development and innovative pharmaceutical strategies indicates a critical shift towards modernization and competitiveness in the industry [3].